The Combination of Radiotherapy With Immunotherapy and Potential Predictive Biomarkers for Treatment of Non-Small Cell Lung Cancer Patients

Frontiers in Immunology

Jianfang Xu¹  Ying Ye²  Shilan Luo²  Yingying Wang²  Xiaomei Gong²  Lu Meng² 

[1] Department of Oncology, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, China;Department of Radiation Oncology, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, China;

关键词: non-small cell lung cancer (NSCLC);    radiotherapy;    immunotherapy;    immune checkpoint inhibitor (ICI);    biomarker;   

DOI  :  10.3389/fimmu.2021.723609

来源: DOAJ

【 摘 要 】

Radiotherapy is an effective local treatment modality of NSCLC. Its capabilities of eliminating tumor cells by inducing double strand DNA (dsDNA) damage and modulating anti-tumor immune response in irradiated and nonirradiated sites have been elucidated. The novel ICIs therapy has brought hope to patients resistant to traditional treatment methods, including radiotherapy. The integration of radiotherapy with immunotherapy has shown improved efficacy to control tumor progression and prolong survival in NSCLC. In this context, biomarkers that help choose the most effective treatment modality for individuals and avoid unnecessary toxicities caused by ineffective treatment are urgently needed. This article summarized the effects of radiation in the tumor immune microenvironment and the mechanisms involved. Outcomes of multiple clinical trials investigating immuno-radiotherapy were also discussed here. Furthermore, we outlined the emerging biomarkers for the efficacy of PD-1/PD-L1 blockades and radiation therapy and discussed their predictive value in NSCLC.

【 授权许可】

Unknown